Prolactin Inhibits BCL6 Expression in Breast Cancer Cells through a MicroRNA-339-5p-Dependent Pathway

Hong Yan, Min Zhao, Shan Huang, Ping Chen, Wenyong Wu, Jin Huang, Zhengsheng Wu, Qiang WuJournal of Breast Cancer 2016 · DOI

Abstract

These results indicated that PRL inhibited BCL6 expression and regulated breast cancer progression through a miR-339-5p-dependent pathway.

Introduction

The proto-oncogene B-cell lymphoma 6 (BCL6) is a significant factor in breast cancer pathology. High levels of BCL6 are associated with larger tumor sizes, increased metastasis, and a poorer prognosis for patients. While Prolactin (PRL) is primarily known for its role in lactation, emerging evidence suggests it may also act as a tumor suppressor by inhibiting BCL6. This study investigates the molecular mechanism behind this inhibition, specifically exploring the role of microRNAs (miRNAs) as mediators of this hormonal signaling.

Methods

The researchers employed human breast cancer cell lines—MCF-7, T47D (luminal ER+ models), and SKBR3 (HER2-overexpressing model)—to study the effects of PRL.

  • Expression Analysis: Quantitative RT-PCR (qRT-PCR) and Western blotting were used to measure BCL6 mRNA and protein levels, respectively.
  • Functional Assays: Cell viability, colony formation, and Transwell migration/invasion assays were conducted to assess phenotypic changes.
  • Pathway Validation: Antisense oligonucleotides (ASOs) were used to knock down miR-339-5p to determine if it is required for PRL-mediated BCL6 suppression.

Results

Prolactin Suppresses BCL6 in a Dose- and Time-Dependent Manner

The study found that PRL treatment significantly reduces BCL6 expression. In T47D cells, BCL6 protein levels decreased as the dose of PRL increased from 0 to 30 nM. Furthermore, time-course experiments in both MCF-7 and T47D cells showed that BCL6 protein and mRNA levels began to decline significantly within 3 to 6 hours of exposure to 10 nM PRL, with the effect persisting up to 48 hours.

Figure 1: Prolactin (PRL) treatment inhibits BCL6 protein and mRNA expression in a dose- and time-dependent manner across T47D and MCF-7 breast cancer cell lines.

The Role of miR-339-5p

The inhibitory effect of PRL on BCL6 was found to be mediated by miR-339-5p. PRL treatment led to a rapid upregulation of miR-339-5p, which inversely correlated with BCL6 levels. Crucially, when miR-339-5p was blocked using ASOs, PRL was no longer able to suppress BCL6 expression or inhibit the oncogenic behaviors (colony formation, migration, and invasion) of the breast cancer cells.

Discussion

This research identifies a novel PRL–miR-339-5p–BCL6 signaling axis. By upregulating miR-339-5p, Prolactin effectively silences the BCL6 oncogene, thereby reducing the proliferation and invasiveness of breast cancer cells. While the study suggests the involvement of the JAK2/STAT5 pathway upstream, the precise transcriptional regulation of the miR-339-5p promoter remains to be fully elucidated. Future in vivo studies and clinical correlations are necessary to validate these findings in a physiological context.

Reference

Yan H, et al. Prolactin Inhibits BCL6 Expression in Breast Cancer Cells through a MicroRNA-339-5p-Dependent Pathway. J Breast Cancer. 2016;19(1):26-33.

Summary updated

Abstract

These results indicated that PRL inhibited BCL6 expression and regulated breast cancer progression through a miR-339-5p-dependent pathway.
BibTeX
@article{yan2016prolactin,
  author = {Hong Yan and Min Zhao and Shan Huang and Ping Chen and Wenyong Wu and Jin Huang and Zhengsheng Wu and Qiang Wu},
  title = {{Prolactin Inhibits <i>BCL6</i> Expression in Breast Cancer Cells through a MicroRNA-339-5p-Dependent Pathway}},
  journal = {Journal of Breast Cancer},
  year = {2016},
  doi = {10.4048/jbc.2016.19.1.26},
}
Figure